Chair, Department of Radiology
Professor, Department of Radiology
To see if Elizabeth Anne Morris is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).
Dr. Morris believes in empowering patients to be active in their care. She believes in patient-centered care as the Institute of Medicine (IOM) defines as "care that is respectful of, and responsive to, individual patient preferences, needs and values, and ensuring that patient values guide all clinical decisions".
Dr. Morris is an internationally recognized expert in breast imaging and has been an active clinician her entire career. She specialized in high risk screening and the use of contrast based screening, including magnetic resonance imaging (MRI) and contrast enhanced digital mammography (CEDM).
She has been listed for multiple years in New York Times Top Doctors, New York Magazine Top Doctors, Best Doctors in America and Castle Connolly's top doctors: New York Metro Area. She is a Komen Scholar.
She is passionate about personalized screening - making sure that all women obtain the screening that is right for them so that cancer can be identified at the earliest stage possible, therby saving lives as well as minimizing treatment (both surgical and oncological). She believes that focusing on early detection is the future of cancer care.
Dr. Morris has conducted expensive research optimizing the use of newer techniques such as magnetic resonance imaging (MRI) to detect breast cancer early, with the goal of finding breast cancer lesions when they are small and treatable.
She is a pioneer in high-risk breast cancer screening. She has authored a book “Breast MRI: Diagnosis & Intervention”. In collaboration with her colleagues she has written over 230 papers, 40 chapters and 5 books about breast disease. Dr. Morris lectures widely both nationally and internationally at over 320 conferences and has mentored over 50 international research fellows. She has grants from NCI, RSNA, Komen Foundation, and Breast Cancer Research Foundation. Her recent research efforts have involved looking at imaging biomarkers to assess risk and treatment response. She is PI of a $3.6 million grant from GRAIL to use circulating fragments of tumor DNA in the plasma to distinguish between benign and malignant BI-RADS 4 lesions in the hopes that some day early detection of breast cancer may be possible before imaging abnormities appear.
B.S., UC Davis, Davis CA 1984
M.D., UC San Francisco, San Francisco CA 1989
Internal Medicine, Mt. Zion Hospital, San Francisco CA 1989-1990
Radiology, Weill Cornell Medical College, New York NY 1990-1994
Breast & Body Imaging, Memorial Sloan Kettering Cancer Center, New York NY 1994-1995
NY Times Top Doctors (multiple years),
NY Magazine Top Doctors (multiple years),
Best Doctors in America (multiple years),
Castle Connolly's Top Doctors: New York Metro Area (multiple years),
Equity Diversity & Inclusion (EDI) officer of the International Society for Magnetics, Resonance in Medicine (ISMRM), 2018, 2019, 2020
To see a complete list of Dr. Morris' publications, please click here.
Zhang M, Sadinski M, Haddad D, Bae MS, Martinez D, Morris EA, Gibbs P, Sutton EJ. Background Parenchymal Enhancement on Breast MRI as a Prognostic Surrogate: Correlation With Breast Cancer Oncotype Dx Score. Front Oncol. 2021 Feb 4;10:595820. doi:10.3389/fonc.2020.595820. PMID:33614481.
Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang ES, Khan SA, Loibl S, Morris EA, Perez A, Regan MM, Spears PA, Sudheendra PK, Symmans WF, Yung RL, Harvey BE, Hershman DL. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. J Clin Oncol. 2021 Jan 28:JCO2003399. doi:10.1200/JCO.20.03399. Online ahead of print. PMID:33507815.
Sutton EJ, Braunstein LZ, El-Tamer MB, Brogi E, Hughes M, Bryce Y, Gluskin JS, Powell S, Woosley A, Tadros A, Sevilimedu V, Martinez DF, Toni L, Smelianskaia O, Nyman CG, Razavi P, Norton L, Fung MM, Sedorovich JD, Sacchini V, Morris EA. Accuracy of Magnetic Resonance Imaging-Guided Biopsy to Verify Breast Cancer Pathologic Complete Response After Neoadjuvant Chemotherapy: A Nonrandomized Controlled Trial. JAMA Netw Open. 2021 Jan 4;4(1):e2034045. doi:10.1001/jamanetworkopen.2020.34045. PMID:33449096.
Saccarelli CR, Bitencourt AGV, Morris EA. Is It the Era for Personalized Screening? Radiol Clin North Am. 2021 Jan;59(1):129-138. doi:10.1016/j.rcl.2020.09.003. Epub 2020 Oct 29. PMID:33222994.
Warnert EAH, Kasper L, Meltzer CC, Lightfoote JB, Bucknor MD, Haroon H, Duggan G, Gowland P, Wald L, Miller KL, Morris EA, Anazodo UC. Resonate: Reaching Excellence Through Equity, Diversity, and Inclusion in ISMRM. J Magn Reson Imaging. 2020 Dec 21. doi:10.1002/jmri.27476. Epub ahead of print. PMID:33350020.
Ochoa-Albiztegui RE, Sevilimedu V, Horvat JV, Thakur SB, Helbich TH, Trattnig S, Morris EA, Reiner JS, Pinker K. Pharmacokinetic Analysis of Dynamic Contrast-Enhanced Magnetic Resonance Imaging at 7T for Breast Cancer Diagnosis and Characterization. Cancers (Basel). 2020 Dec 14;12(12):3763. doi:10.3390/cancers12123763. PMID:33327532.
Watt GP, Sung J, Morris EA, Buys SS, Bradbury AR, Brooks JD, Conant EF, Weinstein SP, Kontos D, Woods M, Colonna SV, Liang X, Stein MA, Pike MC, Bernstein JL. Association of breast cancer with MRI background parenchymal enhancement: the IMAGINE case-control study. Breast Cancer Res. 2020 Dec 7;22(1):138. doi:10.1186/s13058-020-01375-7. PMID:33287857.
Lynch KA, Omisore AD, Atkinson TM, Famurewa OC, Vera JA, Kingham TP, Alatise OI, Hricak H, Morris EA, Sutton EJ; the; African Research Group for Oncology Collaborative. Multistakeholder Needs Assessment to Inform the Development of an mHealth-Based Ultrasound-Guided Breast Biopsy Training Program in Nigeria. JCO Glob Oncol. 2020 Nov;6:1813-1823. doi:10.1200/GO.20.00353. PMID:33216646.
Bitencourt AGV, Gibbs P, Rossi Saccarelli C, Daimiel I, Lo Gullo R, Fox MJ, Thakur S, Pinker K, Morris EA, Morrow M, Jochelson MS. MRI-based machine learning radiomics can predict HER2 expression level and pathologic response after neoadjuvant therapy in HER2 overexpressing breast cancer. EBioMedicine. 2020 Nov;61:103042. doi:10.1016/j.ebiom.2020.103042. Epub 2020 Oct 8. PMID:33039708.